Analysts Anticipate Heron Therapeutics, Inc. (NASDAQ:HRTX) Will Announce Earnings of -$0.45 Per Share

Wall Street brokerages expect Heron Therapeutics, Inc. (NASDAQ:HRTXGet Rating) to report earnings of ($0.45) per share for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Heron Therapeutics’ earnings. The highest EPS estimate is ($0.30) and the lowest is ($0.56). Heron Therapeutics reported earnings of ($0.58) per share in the same quarter last year, which suggests a positive year over year growth rate of 22.4%. The firm is expected to report its next quarterly earnings results after the market closes on Monday, January 1st.

On average, analysts expect that Heron Therapeutics will report full-year earnings of ($1.59) per share for the current financial year, with EPS estimates ranging from ($2.18) to ($0.82). For the next financial year, analysts anticipate that the firm will report earnings of ($0.91) per share, with EPS estimates ranging from ($1.20) to ($0.40). Zacks’ EPS calculations are an average based on a survey of research analysts that cover Heron Therapeutics.

Heron Therapeutics (NASDAQ:HRTXGet Rating) last issued its quarterly earnings results on Monday, February 28th. The biotechnology company reported ($0.54) EPS for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.05. The business had revenue of $20.66 million for the quarter, compared to analyst estimates of $25.77 million. Heron Therapeutics had a negative return on equity of 159.70% and a negative net margin of 255.58%. Heron Therapeutics’s quarterly revenue was up .2% compared to the same quarter last year. During the same period last year, the company posted ($0.68) earnings per share.

Several analysts have issued reports on the company. Zacks Investment Research lowered Heron Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, February 9th. Cowen lowered their target price on Heron Therapeutics from $31.00 to $13.00 in a research note on Tuesday, March 1st. StockNews.com assumed coverage on Heron Therapeutics in a research note on Thursday, March 31st. They issued a “sell” rating on the stock. Cantor Fitzgerald lowered their target price on Heron Therapeutics from $26.00 to $20.00 and set an “overweight” rating on the stock in a research note on Tuesday, March 1st. Finally, Needham & Company LLC lowered their target price on Heron Therapeutics from $24.00 to $16.00 in a research note on Tuesday, March 1st. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Heron Therapeutics has an average rating of “Hold” and an average price target of $18.46.

A number of institutional investors have recently bought and sold shares of HRTX. Zullo Investment Group Inc. purchased a new position in Heron Therapeutics during the fourth quarter worth about $30,000. Dark Forest Capital Management LP grew its position in Heron Therapeutics by 3,258.7% during the third quarter. Dark Forest Capital Management LP now owns 3,090 shares of the biotechnology company’s stock worth $33,000 after buying an additional 2,998 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. purchased a new position in Heron Therapeutics during the third quarter worth about $37,000. Russell Investments Group Ltd. purchased a new position in Heron Therapeutics during the fourth quarter worth about $39,000. Finally, Point72 Hong Kong Ltd grew its position in Heron Therapeutics by 241.1% during the third quarter. Point72 Hong Kong Ltd now owns 6,787 shares of the biotechnology company’s stock worth $73,000 after buying an additional 4,797 shares in the last quarter.

Shares of Heron Therapeutics stock opened at $4.11 on Friday. The business’s fifty day simple moving average is $5.39 and its 200 day simple moving average is $7.97. The company has a current ratio of 3.58, a quick ratio of 2.90 and a debt-to-equity ratio of 1.92. Heron Therapeutics has a 12 month low of $3.95 and a 12 month high of $18.80.

Heron Therapeutics Company Profile (Get Rating)

Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

See Also

Get a free copy of the Zacks research report on Heron Therapeutics (HRTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.